Intravenous pharmacokinetics and in vitro bactericidal activity of trimethoprim-sulfamethoxazole.
Trimethoprim-sulfamethoxazole (240 mg of trimethoprim plus 1,200 mg of sulfamethoxazole) was administered intravenously in a volume of 200 ml to 7 volunteers every 12 hr for 4 days. The mean peak levels of TMP and SMZ in plasma were 3.22 and 100 micrograms/ml, respectively, on day 1 and 5.91 and 178 micrograms/ml, respectively, on day 4, when a steady state was achieved. Tests of in vitro susceptibility indicated that these concentrations are bactericidal for a large proportion of enteric gram-negative bacilli.
D000328:Adult; D001419:Bacteria / Q000187:drug effects*; D004338:Drug Combinations / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology; D006207:Half-Life; D006801:Humans; D007263:Infusions, Parenteral; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D013210:Staphylococcus / Q000187:drug effects; D013420:Sulfamethoxazole / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood* / Q000494:pharmacology; D014295:Trimethoprim / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood* / Q000494:pharmacology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole